To include your compound in the COVID-19 Resource Center, submit it here.

Orphan opportunity

Why KKR returned to co-lead Orphan play BridgeBio's $135M round

Private equity giant KKR returned to co-lead BridgeBio Pharma LLC's $135 million venture round, which could enable the Orphan play to double its pipeline in the next two years.

KKR co-led the Sept.

Read the full 335 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE